Login / Signup

Adaptively leverage multiple real-world data sources for treatment effect estimation based on similarity.

Meihua LongJiali SongZhiwei RongLan MiYuqin SongYan Hou
Published in: Journal of biopharmaceutical statistics (2024)
The incorporation of real-world data (RWD) into medical product development and evaluation has exhibited consistent growth. However, there is no universally adopted method of how much information to borrow from external data. This paper proposes a study design methodology called Tree-based Monte Carlo (TMC) that dynamically integrates patients from various RWD sources to calculate the treatment effect based on the similarity between clinical trial and RWD. Initially, a propensity score is developed to gauge the resemblance between clinical trial data and each real-world dataset. Utilizing this similarity metric, we construct a hierarchical clustering tree that delineates varying degrees of similarity between each RWD source and the clinical trial data. Ultimately, a Gaussian process methodology is employed across this hierarchical clustering framework to synthesize the projected treatment effects of the external group. Simulation result shows that our clustering tree could successfully identify similarity. Data sources exhibiting greater similarity with clinical trial are accorded higher weights in treatment estimation process, while less congruent sources receive comparatively lower emphasis. Compared with another Bayesian method, meta-analytic predictive prior (MAP), our proposed method's estimator is closer to the true value and has smaller bias.
Keyphrases
  • clinical trial
  • electronic health record
  • big data
  • open label
  • study protocol
  • randomized controlled trial
  • machine learning
  • double blind
  • prognostic factors
  • phase ii
  • newly diagnosed
  • rna seq
  • deep learning